FB 04 - Universitätsmedizin
Johannes Gutenberg-Universität Mainz
- 06131/17-9704 oder 9799 (Sekretariat)
- 06131/17-9669
Hanganu, IL; Okabe, A; Lessmann, V et al.
Cellular mechanisms of subplate-driven and cholinergic input-dependent network activity in the neonatal rat somatosensory cortex.Cereb Cortex. Bd. 19. H. 1. 2009 S. 89-105
Lignitz, S; Partsch, CJ; Wudy, SA et al.
Central precocious puberty after pseudo-precocious puberty due to a Leydig cell tumor of the testis in a six year old boyHORMONE RESEARCH. Bd. 72. 2009 S. 267-267
Moreira, FA; Grieb, M; Lutz, B
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.Best Pract Res Clin Endocrinol Metab. Bd. 23. H. 1. 2009 S. 133-44
Klein, KU; Fukui, K; Schramm, P et al.
Cerebral microcirculation and oxygenation remain unchanged durign propofol-induced reduction in bispetral indexJ Neurosurg Anesth. Bd. 21. 2009 S. 409
Klein, KU; Fukui, K; Schramm, P et al.
Cerebral microcirculation remains unchanged during propofol-induced reduction in bispectral indexAnesthesiology. Bd. 111. 2009 S. CD A 518
Wentzensen, N; Klug, SJ
Cervical cancer control in the era of HPV vaccination and novel biomarkersPathobiology. Bd. 76. H. 2. 2009 S. 82-89
Lorenzen, S; Schuster, T; Porschen, R et al.
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieAnn Oncol. Bd. 20. H. 10. 2009 S. 1667
Moehler, M; Trarbach, T; Seufferlein, T et al.
CETUXIMAB WITH IRINOTECAN/FOLINIC ACID/5-FU AS FIRST-LINE TREATMENT IN ADVANCED GASTRIC CANCER: A NON-RANDOMISED MULTI-CENTER AID PHASE II STUDYANNALS OF ONCOLOGY. Bd. 20. 2009 S. 25-25
Kanzler, S; Trarbach, T; Seufferlein, T et al.
Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II studyJOURNAL OF CLINICAL ONCOLOGY. Bd. 27. H. 15. 2009 S. -
Mohler, M; Mueller, A; Trarbach, T et al.
Cetuximab with Irinotecan/Folinic Acid/5-FU as first-line treatment in advanced gastric cancer: a prospective multi-center phase II study and additional biomarkers of the Arbeitsgemeinschaft Internistische OnkologieEJC SUPPLEMENTS. Bd. 7. H. 2. 2009 S. 384-384